MedCity News
4 takeaways from 23&Me’s planned SPAC deal
Consumer DNA testing company 23andMe plans to go public through a merger with a special-purpose acquisition company started by Virgin Group. As sales of DNA testing kits wane, how will 23andMe drum up new interest for its business?
Shares0
As sales for DNA testing kits flatten, the companies that make them are faced with a predicament. Revenues are falling as the market became saturated, and more consumers began to wonder about the privacy of their data.
After a bumpy 2020, consumer DNA testing company 23andMe plans to go public through a blank-check deal. The Sunnyvale, Calif.-based business will merge with a special-purpose acquisition company started by Virgin Group in a deal that would value it at $3.5 billion.
Patient volumes were uneven in 2020, and a new report shows volumes will likely remain below pre-pandemic levels in 2021. This indicates challenges for hospitals looking to stabilize their finances but there are some key strategies that can help.
Share /
Feb 7, 2021 at 10:04 AM
Promoted
In order to gain insight into how organizations are thinking about digitizing medical documents and the strategy behind those decisions, we’re conducting a brief survey of the MedCity News audience and will publish a report based on this survey’s findings.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.